Global Cardio Oncology Registry
The Cleveland Clinic · NCT05598879
This study is collecting health information from cancer patients around the world to see what factors might increase their risk of heart problems caused by cancer treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The Cleveland Clinic (other) |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Weston, Florida) |
| Trial ID | NCT05598879 on ClinicalTrials.gov |
What this trial studies
The Global Cardio Oncology Registry (G-COR) is a multinational, multicenter observational cohort registry aimed at collecting comprehensive data on cancer patients to identify risk factors for cardiovascular toxicity related to cancer therapies. It will gather clinical, laboratory, imaging, demographic, and socioeconomic information from 124 hospitals across 24 countries. The registry focuses on three populations: patients with hematological malignancies, breast cancer, and those treated with immune checkpoint inhibitors. By analyzing this data, G-COR seeks to derive and validate risk scores for cardiovascular complications in diverse geographic settings.
Who should consider this trial
Good fit: Ideal candidates include adult patients (18 years and older) undergoing new cardio-oncology consultations for breast cancer, hematological malignancies, or those evaluated for immune checkpoint inhibitors.
Not a fit: Patients who have previously undergone cardio-oncology evaluations or are under 18 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could lead to improved risk assessment and management strategies for cancer patients at risk of cardiovascular toxicity.
How similar studies have performed: Other studies have shown success in similar observational approaches, but G-COR represents a novel and extensive international effort in this field.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * New cardio-oncology consultation for breast cancer patients, or * New cardio-oncology consultation for Hodgkin's or non-Hodgkin's lymphoma patients, or * New cardio-oncology consultation for acute or chronic leukemia patients, or * New cardio-oncology consultation for multiple myeloma or AL amyloidosis, or * New cardio-oncology consultations for immune check-point inhibitors cardiac evaluation. * All patients have to be 18 years old or older Exclusion Criteria: * Cardio-oncology patients who have previously had cardio-oncology evaluation and follow up by the investigators. * Minors less than 18 years old. * Inability or unwillingness to consent to participate
Where this trial is running
Weston, Florida
- Cleveland Clinic Florida — Weston, Florida, United States (RECRUITING)
Study contacts
- Principal investigator: Diego Sadler, MD FACC — The Cleveland Clinic
- Study coordinator: Diego Sadler, MD FACC
- Email: sadlerd@ccf.org
- Phone: 5613898833
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Breast Cancer, Hematologic Malignancy, Immune Checkpoint Inhibitor-Related Myocarditis, Cardiotoxicity, Cardiovascular Diseases, cardiotoxicity, Cancer related cardiovascular diseases, prospective registry